Abstract
Over the past decade, increasing attention has been paid to the proper assessment and evaluation of health-related quality of life in men with prostate cancer. A major motivation for this work is the lack of strong evidence that survival end-points differ among the various therapies in the setting of documented differences in morbidities. This review summarizes the current literature regarding the evaluation of health-related quality of life for prostate cancer. The use of validated measures and other issues relevant for prostate cancer-specific assessments will be discussed.